10:21:04 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-02-28 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-15 Ordinarie utdelning ISAB 0.00 SEK
2023-05-12 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2


Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2023-04-19 10:34:15

(Stockholm, Sweden, 19 April 2023) Following its highly successful webinar on DissolvIt dissolution studies on March 30[th] - 300 people registered - Inhalation Sciences AB (ISAB) will release two new webinars in 2023. Each will be partnered and co-presented by an industry expert. The next, on May 2[nd] 2023, features in vivo exposures for inhaled medicines with ISAB's PreciseInhale aerosol system showcased by Per Gerde, ISAB's CSO and Founder, and inhalation expert Matt Reed from Coelus Bio. Register for the seminar below.

ISAB is partnering with industry experts in two new webinars in its popular series. The latest webinar, on its unique in vitro module, the DissolvIt method, was extremely well-received, attracting 300 subscribers. It was co-presented by bioanalytic consultant Prof Hermann Mascher, together with ISAB's in vitro specialist and Director of Projects Dr. Maria Malmlöf. Watch the webinar HERE. (https://callboxinc.zoom.us/rec/play/txFzsiw0TM_MlKCIYHpWPVz7yanvF2MAR0KAV1I94VE9o8BOu-A6S6t3vqNiaTFCIuo7wlq9RVvMR-3B.9tTwXYogR0W3IAOh?canPlayFromShare=true&from=share_recording_detail&continueMode=true&componentName=rec-play&originRequestUrl=https%3A%2F%2Fcallboxinc.zoom.us%2Frec%2Fshare%2FHbpyDRgfFQJ1eBK5NJKcExbbdogfJNtMwQLAn98FTgk8BsfjHHnXjjIbDvZql0Z9.QVS-OCRuBXDom8EM)

Webinar #2: May 2[nd] 2023

ISAB will present its next webinar, on in vivo studies, on May 2[nd] 2023 . It will be co-presented by an expert in the field - Matt Reed from Coelus Bio. Matt is a pharmacologist and a board-certified toxicologist with over 25 years' experience in which he has been a part of multiple successful R&D programs that that have transitioned to regulatory approval for small molecules, biologics, oligonucleotides

Register for the May 2[nd] webinar HERE (https://callboxinc.zoom.us/webinar/register/WN_qIrfa4y8QLumAezMXSPCyQ#/registration)

ISAB offers a competitive range of in vivo testing solutions, including its unique intratracheal module. The module uses a catheter connected to PreciseInhale that bypasses the nasal airways, ensuring test substances are retained in the lung and delivering high-precision data of, typically, <10% Standard Deviation.

Webinar #3 - customer partner

ISAB's third expert webinar is expected to be presented later in Fall 2023.

CEO Manoush Masarrat: "These webinars are a superb showcase of our unique expertise and capabilities. I would urge anyone in inhaled pharmaceutical development who is interested in de-risking their drug development early on to register and take part. Our inhalation research services (IRS) are an important key to growth for us, as we share our knowledge and capabilities we build partnerships, increase sales and accelerate our sales cycles."